CORBUS PHARMACEUTICALS HOLDI
CRBPNASDAQ🏆 #3055 by market capUS Equity
$9.51▲ $0.03 (+0.32%)
Market closed · at close1h—
24h▲ 0.3%
7d▼ 0.5%
14d▲ 6.6%
30d▲ 5.0%
1y▲ 6.4%
🏦Market Cap
$176M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
119.4x
Expensive
Otter Score
44
Weak
Trading Snapshot
- Day Range
- $9.39 – $9.57
- 52-Week Range
- $7.12 – $20.56
- Volume
- $4.04B
- Avg Volume
- $3.76B
- Shares Outstanding
- 18.5M
- Next Earnings
- Oct 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $425,360
- P/E Ratio
- —
- P/S Ratio
- 119.4x
- EPS (TTM)
- $-6.17
- Dividend Yield
- —
Why Investors Own CRBP
- ✓High-growth profile — revenue up -8.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 40% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$2M▼ −12.1% YoY
Gross Margin (TTM)
39.9%▲ +0.9% YoY
Operating Income (TTM)
$161,730▼ −12.1% YoY
Free Cash Flow (TTM)
$77,014▼ −12.1% YoY
About CORBUS PHARMACEUTICALS HOLDI
A company profile for CORBUS PHARMACEUTICALS HOLDI isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
44/100
Analyst Price Target
ⓘAverage Target
$10.42
▲ +9.6% Upside
High Target$11.98
Low Target$8.12
Based on 31 analysts
Latest News & Updates
🚀
CNBC·2h ago
CORBUS PHARMACEUTICALS HOLDI tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift CRBP price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
CORBUS PHARMACEUTICALS HOLDI announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.